Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Positive efficacy/safety profile for maximal-dose sulfonylurea therapy reported

Aug. 30, 1996

Beta3-adrenoceptor agonists described by Dainippon

Aug. 30, 1996

Cangene and Cheil Jedang sign Leucotropin agreement

Aug. 30, 1996

CCK antagonists from Warner-Lambert

Aug. 30, 1996

NGD-95-1 demonstrates safety in phase I

Aug. 30, 1996

More squalene synthase inhibitors from Pfizer

Aug. 30, 1996

Xenical to be marketed in 1997

Aug. 30, 1996

SDZ-266806: A novel squalene synthase inhibitor

Aug. 30, 1996

Estrogenic compounds from Sankyo

Aug. 30, 1996

Prophylactic tibolone shown effective in 2 year study

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...